MCID: LNG039
MIFTS: 65

Lung Squamous Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Lung Squamous Cell Carcinoma

MalaCards integrated aliases for Lung Squamous Cell Carcinoma:

Name: Lung Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Lung 12 71
Squamous Cell Lung Carcinoma 6 17
Epidermoid Cell Carcinoma of the Lung 12
Squamous Cell Lung Cancer 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3907
NCIt 49 C3493
UMLS 71 C0149782

Summaries for Lung Squamous Cell Carcinoma

Disease Ontology : 12 A non-small cell lung carcinoma that has material basis in the squamous cell.

MalaCards based summary : Lung Squamous Cell Carcinoma, also known as squamous cell carcinoma of lung, is related to squamous cell carcinoma and adenocarcinoma. An important gene associated with Lung Squamous Cell Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are TGF-Beta Pathway and Developmental Biology. The drugs Nedaplatin and afatinib have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and thyroid, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC).... more...

Related Diseases for Lung Squamous Cell Carcinoma

Diseases related to Lung Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 423)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 32.3 TUG1 TP53 SOX2-OT PTEN PIK3CA NFE2L2
2 adenocarcinoma 32.3 TP53 PTEN PIK3CA KRAS HRAS FGFR3
3 lung cancer 31.9 TUG1 TP53 TERC SOX2-OT SNHG1 PVT1
4 small cell carcinoma 31.7 TP53 PTEN KRAS EGFR
5 lung cancer susceptibility 3 31.6 TUG1 TP53 SFTA1P PTEN PIK3CA NFE2L2
6 papilloma 31.5 TP53 PTEN KRAS FGFR3 EGFR
7 papillary adenocarcinoma 31.2 TP53 NFE2L2 KRAS
8 breast adenocarcinoma 31.2 TP53 PIK3CA KRAS EGFR
9 adenosquamous carcinoma 31.1 TP53 PTEN PIK3CA KRAS EGFR
10 large cell carcinoma 31.1 KRAS HRAS EGFR
11 in situ carcinoma 31.1 TP53 PTEN HRAS EGFR
12 lung benign neoplasm 31.1 TP53 KRAS HRAS EGFR
13 thyroid gland anaplastic carcinoma 31.1 TP53 PTEN PIK3CA BRAF
14 squamous cell papilloma 31.0 TP53 HRAS
15 thymoma 31.0 TP53 PIK3CA HRAS EGFR
16 signet ring cell adenocarcinoma 31.0 TP53 KRAS HRAS
17 obsolete: squamous cell carcinoma of head and neck 31.0 TP53 PTEN PIK3CA NFE2L2 HRAS FGFR3
18 exanthem 30.9 KRAS HRAS EGFR
19 colorectal adenocarcinoma 30.9 TP53 PTEN KRAS HRAS EGFR BRAF
20 glioblastoma multiforme 30.8 TP53 PTEN PIK3CA KRAS HRAS EGFR
21 transitional cell carcinoma 30.8 TP53 PTEN HRAS FGFR3 EGFR BRAF
22 lung adenoma 30.8 TP53 PTEN KRAS HRAS EGFR
23 adenoid cystic carcinoma 30.8 TP53 PTEN PIK3CA KRAS HRAS EGFR
24 retinitis pigmentosa 11 30.8 TP53 PVT1 PTEN HRAS EGFR
25 thyroid carcinoma 30.8 TP53 PTEN PIK3CA HRAS BRAF
26 kidney cancer 30.8 TP53 PVT1 PTEN PIK3CA NFE2L2 EGFR
27 skin melanoma 30.7 TP53 PTEN HRAS BRAF
28 small cell cancer of the lung 30.7 TUG1 TP53 PTEN PIK3CA EGFR
29 lymphoma 30.6 TP53 PVT1 PTPN11 PIK3CA EGFR BRAF
30 neuroblastoma 30.6 TP53 SNHG1 PTPN11 PTEN PIK3CA NFE2L2
31 cholangiocarcinoma 30.5 TUG1 TP53 SOX2-OT PTEN PIK3CA KRAS
32 hypertrophic cardiomyopathy 30.5 PTPN11 KRAS HRAS BRAF
33 leukemia, chronic lymphocytic 30.5 TP53 PTPN11 PTEN KRAS HRAS EGFR
34 malignant pleural mesothelioma 30.5 TP53 PVT1 EGFR
35 glioma 30.5 TP53 PVT1 PTEN PIK3CA EGFR CCAT1
36 intrahepatic cholangiocarcinoma 30.4 TUG1 TP53 PTEN KRAS FGFR2 EGFR
37 melanoma 30.3 TP53 SOX2-OT PVT1 PTEN PIK3CA KRAS
38 nasopharyngeal carcinoma 30.1 TP53 PVT1 PTEN PIK3CA HRAS EGFR
39 lymphocytic leukemia 30.1 TP53 PTPN11 KRAS BRAF
40 myelodysplastic syndrome 29.9 TP53 TERC PTPN11 PTEN KRAS HRAS
41 bladder cancer 29.8 TUG1 TP53 TERC PVT1 PTEN PIK3CA
42 renal cell carcinoma, nonpapillary 29.8 TUG1 TP53 PVT1 PTEN PIK3CA HRAS
43 leukemia, acute myeloid 29.8 TUG1 TP53 PTPN11 PTEN KRAS HRAS
44 myeloma, multiple 29.5 TUG1 TP53 PVT1 PTPN11 PTEN KRAS
45 breast cancer 29.3 TUG1 TP53 SOX2-OT PVT1 PTPN11 PTEN
46 gastric cancer 29.0 TUG1 TP53 TERC SOX2-OT SNHG1 SFTA1P
47 hepatocellular carcinoma 28.9 TUG1 TP53 TERC SOX2-OT SNHG1 PVT1
48 lung occult squamous cell carcinoma 11.5
49 lung mixed small cell and squamous cell carcinoma 11.5
50 adenoma 11.0 TP53 PIK3CA KRAS BRAF

Graphical network of the top 20 diseases related to Lung Squamous Cell Carcinoma:



Diseases related to Lung Squamous Cell Carcinoma

Symptoms & Phenotypes for Lung Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.56 EGFR HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00106-A-0 10.56 KRAS
3 Decreased viability GR00221-A-1 10.56 EGFR FGFR3 HRAS KRAS PIK3CA
4 Decreased viability GR00221-A-2 10.56 FGFR3 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.56 FGFR3 HRAS
6 Decreased viability GR00221-A-4 10.56 EGFR PIK3CA BRAF
7 Decreased viability GR00301-A 10.56 KRAS BRAF
8 Decreased viability GR00381-A-1 10.56 KRAS BRAF
9 Decreased viability GR00402-S-2 10.56 EGFR FGFR3 HRAS KRAS PIK3CA BRAF
10 Decreased cell migration GR00055-A-1 9.8 BRAF EGFR FGFR3 HRAS KRAS PIK3CA
11 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.73 EGFR FGFR2 FGFR3 HRAS PTEN PTPN11
12 Increased cell migration GR00055-A-3 9.35 BRAF EGFR HRAS KRAS PIK3CA
13 Reduced mammosphere formation GR00396-S 9.17 BRAF EGFR HRAS KRAS NFE2L2 PTEN

MGI Mouse Phenotypes related to Lung Squamous Cell Carcinoma:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.28 BRAF EGFR FGFR2 HRAS KRAS NFE2L2
2 digestive/alimentary MP:0005381 10.27 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
3 integument MP:0010771 10.26 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
4 craniofacial MP:0005382 10.23 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
5 embryo MP:0005380 10.21 BRAF EGFR FGFR2 KRAS NFE2L2 PIK3CA
6 endocrine/exocrine gland MP:0005379 10.2 BRAF EGFR FGFR2 HRAS KRAS PIK3CA
7 neoplasm MP:0002006 10.2 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
8 adipose tissue MP:0005375 10.19 BRAF EGFR FGFR2 NFE2L2 PIK3CA PTEN
9 nervous system MP:0003631 10.17 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
10 limbs/digits/tail MP:0005371 10.11 BRAF EGFR FGFR2 FGFR3 KRAS PTEN
11 liver/biliary system MP:0005370 10.1 BRAF EGFR FGFR2 KRAS NFE2L2 PTEN
12 hearing/vestibular/ear MP:0005377 10.08 BRAF EGFR FGFR2 FGFR3 KRAS PTPN11
13 muscle MP:0005369 10.08 BRAF EGFR FGFR2 KRAS PIK3CA PTEN
14 normal MP:0002873 10.07 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
15 no phenotypic analysis MP:0003012 10.01 EGFR FGFR2 FGFR3 HRAS KRAS PIK3CA
16 renal/urinary system MP:0005367 9.91 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
17 pigmentation MP:0001186 9.87 BRAF EGFR FGFR2 KRAS PTEN PTPN11
18 respiratory system MP:0005388 9.85 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
19 skeleton MP:0005390 9.7 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
20 vision/eye MP:0005391 9.28 BRAF EGFR FGFR2 FGFR3 KRAS PIK3CA

Drugs & Therapeutics for Lung Squamous Cell Carcinoma

Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nedaplatin Approved, Investigational Phase 4 95734-82-0
2
afatinib Approved Phase 4 850140-72-6, 439081-18-2 10184653
3
Apatinib Phase 4 811803-05-1
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Osimertinib Approved Phase 2, Phase 3 1421373-65-0 71496458
6
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
7
Vinblastine Approved Phase 3 865-21-4 13342 241903
8
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
9
Talazoparib Approved, Investigational Phase 2, Phase 3 1207456-01-6 135565082
10
Palbociclib Approved, Investigational Phase 2, Phase 3 571190-30-2 11431660 5005498 5330286
11
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
12
nivolumab Approved Phase 3 946414-94-4
13
Ipilimumab Approved Phase 3 477202-00-9
14
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
15
leucovorin Approved Phase 3 58-05-9 6006 143
16
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
17
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
18
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
19
Lenograstim Approved, Investigational Phase 3 135968-09-1
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
21
Iniparib Investigational Phase 3 160003-66-7
22
Tirapazamine Investigational Phase 3 27314-97-2
23
Tremelimumab Investigational Phase 2, Phase 3 745013-59-6
24
Rilotumumab Investigational Phase 2, Phase 3 872514-65-3
25 Endostar protein Phase 3
26 Endostatins Phase 3 71581480
27 Etoposide phosphate Phase 3
28 Topoisomerase Inhibitors Phase 3
29 Hematinics Phase 3
30 Epoetin alfa Phase 3 113427-24-0
31 Immunoglobulin G Phase 2, Phase 3
32 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
33
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
34 Pharmaceutical Solutions Phase 2, Phase 3
35 Vaccines Phase 2, Phase 3
36 Anti-Bacterial Agents Phase 3
37 Vitamin B Complex Phase 3
38 Folic Acid Antagonists Phase 3
39 Vitamin B9 Phase 3
40 Folate Phase 3
41 Antirheumatic Agents Phase 3
42 Angiogenesis Inhibitors Phase 3
43 Analgesics Phase 3
44 Analgesics, Non-Narcotic Phase 3
45 Anti-Inflammatory Agents, Non-Steroidal Phase 3
46 Cyclooxygenase 2 Inhibitors Phase 3
47 Anti-Inflammatory Agents Phase 3
48 Cyclooxygenase Inhibitors Phase 3
49
Bleomycin Approved, Investigational Phase 2 11056-06-7 5360373
50
Necitumumab Approved, Investigational Phase 2 906805-06-9

Interventional clinical trials:

(show top 50) (show all 213)
# Name Status NCT ID Phase Drugs
1 Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
2 An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation Recruiting NCT04132102 Phase 4 Afatinib
3 A Multicenter, Randomized, Open-label, Parallel-group Study of Paclitaxel Liposome Injection and Cisplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung Not yet recruiting NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
4 Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above Not yet recruiting NCT03725423 Phase 4 Apatinib
5 Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3) Unknown status NCT03150875 Phase 3 Docetaxel
6 Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
7 Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer :A Randomized, Open, Parallel, Multicentre, Phase Ⅲ Study Unknown status NCT02643407 Phase 3 Docetaxel;Nedaplatin;Cisplatin
8 The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration. Unknown status NCT02283476 Phase 3 Endostar continuous intravenous infusion;Endostar routine intravenous infusion;Gemcitabine;Cisplatin
9 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
10 Induction Pemetrexed and Cisplatin Followed by Pemetrexed as Maintenance vs Carboplatin-paclitaxel and Bevacizumab Followed by Bevacizumab as Maintenance:Multicenter Randomized Phase III Study in Patients With Advanced Non-Squamous Non Small-cell Lung Cancer: a Quality of Life Oriented Phase III Trial of the GOIM Unknown status NCT01303926 Phase 3 cisplatin pemetrexed;carboplatin paclitaxel bevacizumab
11 Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) Completed NCT01082549 Phase 3 gemcitabine/carboplatin;gemcitabine/carboplatin plus Iniparib
12 A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma Completed NCT00003901 Phase 3
13 Phase III Study of Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer Completed NCT02959749 Phase 2, Phase 3 Osimertinib;docetaxel, bevacizumab
14 Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
15 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma Completed NCT00003831 Phase 3
16 A Phase III Trial of Single Versus Fractionated Thoracic Radiation for Palliation of Symptoms in Patients With Non-Small Cell Lung Cancer Completed NCT00003685 Phase 3
17 Single-Agent Versus Combination Chemotherapy in Advanced NSCLC: A CALGB Randomized Trial of Efficacy, Quality of Life, and Cost-Effectiveness Completed NCT00003117 Phase 3 carboplatin;paclitaxel
18 Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
19 Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
20 A Phase III Trial of Induction Paclitaxel and Carboplatin Followed By Standard Radiotherapy (64 Gy/7 Weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 Weeks) For Patients With Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer Completed NCT00003235 Phase 3 carboplatin;paclitaxel
21 A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
22 A Randomized Phase III Trial of Erlotinib Versus Docetaxel in Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Who Failed First Line Platinum Based Doublet Chemotherapy Stratified by VeriStrat Good vs VeriStrat Poor Completed NCT01652469 Phase 3 Erlotinib;Docetaxel
23 A Phase III Randomized Trial Evaluating the Effect of Epoetin Alfa (Procrit) on Local Control in Patients Undergoing Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
24 RANDOMIZED TRIAL OF SURGERY VERSUS RADIOTHERAPY IN PATIENTS WITH STAGE IIIa NON-SMALL CELL LUNG CANCER AFTER A RESPONSE TO INDUCTION-CHEMOTHERAPY Completed NCT00002623 Phase 3 carboplatin;cisplatin
25 A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
26 Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
27 A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study) Active, not recruiting NCT02785952 Phase 3
28 A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-Map Sub-Study) Active, not recruiting NCT02766335 Phase 2, Phase 3 Docetaxel
29 A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map) Active, not recruiting NCT02154490 Phase 2, Phase 3 Docetaxel;Erlotinib Hydrochloride;FGFR Inhibitor AZD4547;Palbociclib;Talazoparib;Taselisib
30 A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Active, not recruiting NCT02926638 Phase 2, Phase 3 Erlotinib Hydrochloride
31 A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Active, not recruiting NCT02965378 Phase 2, Phase 3 Docetaxel;FGFR Inhibitor AZD4547
32 A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Active, not recruiting NCT02785939 Phase 2, Phase 3 Docetaxel;Palbociclib
33 A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
34 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Non-small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase III Trial Active, not recruiting NCT00030771 Phase 3 Chemotherapy
35 Proteome-based Personalized Immunotherapy of Brain Metastases From Lung Cancer Enrolling by invitation NCT01782287 Phase 2, Phase 3
36 Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly (More Than 70 Years Old) Patients With Advanced Non-small Cell Lung Cancer Not yet recruiting NCT03351361 Phase 3 Nivolumab + Ipilimumab;Chemotherapy
37 A Randomized Phase III Study of TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer Terminated NCT01282151 Phase 3 Taxotere;Pemetrexed
38 A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients With Early Stage Non-Small Cell Lung Cancer Associated With Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
39 A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
40 Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
41 A Randomized Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
42 A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
43 Photodynamic Therapy for the Prevention of Lung Cancer (PEARL) Withdrawn NCT03346304 Phase 2, Phase 3
44 A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
45 An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer Unknown status NCT02009605 Phase 2 Icotinib
46 Boanmycin Hydrochloride for Injection in Combination With Docetaxel for Patients With Advanced Lung Squamous Cell Carcinoma as Salvage Chemotherapy: a Prospective, Randomized, Parallel and Controlled Clinical Trial Unknown status NCT01660399 Phase 2 Boanmycin;Docetaxel
47 Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung: Parallel Control and Single Center Unknown status NCT01872403 Phase 2 nanoparticle albumin-bound paclitaxel/carboplatin
48 A Phase II Trial of Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer After Failure of Platinum Doublet (Except Pemetrexed) Therapy Unknown status NCT01969955 Phase 2 nanoparticle albumin-bound paclitaxel
49 A Phase II Study of Concurrent Nab-Paclitaxel, Carboplatin and Thoracic Radiotherapy in Local Advanced Squamous Cell Lung Cancer Unknown status NCT01494415 Phase 2 Paclitaxel for Injection(Albumin Bound);carboplatin
50 Phase II Study of Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin/Cisplatin in Stage Ⅱ B and IIIA Non-small Cell Lung Cancer Patients Unknown status NCT02016209 Phase 2 nanoparticle albumin-bound paclitaxel

Search NIH Clinical Center for Lung Squamous Cell Carcinoma

Genetic Tests for Lung Squamous Cell Carcinoma

Anatomical Context for Lung Squamous Cell Carcinoma

MalaCards organs/tissues related to Lung Squamous Cell Carcinoma:

40
Lung, Breast, Thyroid, T Cells, Brain, Lymph Node, Skin

Publications for Lung Squamous Cell Carcinoma

Articles related to Lung Squamous Cell Carcinoma:

(show top 50) (show all 1653)
# Title Authors PMID Year
1
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. 61 6
6695174 1984
2
A comparison of serum CYFRA 21-1 and SCC Ag in the diagnosis of squamous cell lung carcinoma. 54 61
8882476 1996
3
First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations. 61
31810534 2020
4
Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. 61
31855703 2020
5
Cullin 3 overexpression inhibits lung cancer metastasis and is associated with survival of lung adenocarcinoma. 61
31463796 2020
6
Identification SYT13 as a novel biomarker in lung adenocarcinoma. 61
31625195 2020
7
Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC). 61
31837325 2020
8
TRIM59 as a novel molecular biomarker to predict the prognosis of patients with NSCLC. 61
31966070 2020
9
Multi-omics analysis at epigenomics and transcriptomics levels reveals prognostic subtypes of lung squamous cell carcinoma. 61
32036209 2020
10
Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma. 61
31891239 2020
11
Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma. 61
31694906 2020
12
(+)-Usnic Acid Induces ROS-dependent Apoptosis via Inhibition of Mitochondria Respiratory Chain Complexes and Nrf2 Expression in Lung Squamous Cell Carcinoma. 61
32013250 2020
13
Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma. 61
31968252 2020
14
Long Noncoding MAGI2-AS3 Suppresses Several Cellular Processes of Lung Squamous Cell Carcinoma Cells by Regulating miR-374a/b-5p/CADM2 Axis. 61
32021443 2020
15
Co-Expression Network Analysis Identified Genes Associated with Cancer Stem Cell Characteristics in Lung Squamous Cell Carcinoma. 61
31770041 2020
16
CircTIMELESS regulates the proliferation and invasion of lung squamous cell carcinoma cells via the miR-136-5p/ROCK1 axis. 61
31960961 2020
17
Study on the biochemical mechanisms of the micro-wave ablation treatment of lung cancer by ex vivo confocal Raman microspectral imaging. 61
31782420 2020
18
Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report. 61
31921440 2020
19
A Rare Pancreatic Tail Metastasis from Squamous Cell Lung Carcinoma Diagnosed by EUS-FNB and a Small Review of the Literature. 61
31970237 2020
20
Pathological complete response of initially inoperable lung squamous cell carcinoma treated by immunochemotherapy: A case report. 61
31718877 2020
21
Methylation‑driven genes PMPCAP1, SOWAHC and ZNF454 as potential prognostic biomarkers in lung squamous cell carcinoma. 61
32016477 2020
22
Psoas muscle mass in patients undergoing lung cancer surgery: a prognostic difference between squamous cell carcinoma and adenocarcinoma. 61
31955305 2020
23
Identifying critical state of complex diseases by single-sample Kullback-Leibler divergence. 61
31992202 2020
24
Secondary Hypertrophic Osteoarthropathy Associated With Pediatric Primary Lung Squamous Cell Carcinoma. 61
29652703 2020
25
Development of an autophagy-related gene prognostic signature in lung adenocarcinoma and lung squamous cell carcinoma. 61
31938577 2020
26
Identification of dynamic signatures associated with smoking-related squamous cell lung cancer and chronic obstructive pulmonary disease. 61
31829519 2020
27
Comprehensive Analysis of Aberrantly Expressed Profiles of lncRNAs and miRNAs with Associated ceRNA Network in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. 61
31898160 2020
28
A seven long-noncoding RNA signature predicts prognosis of lung squamous cell carcinoma. 61
31729251 2020
29
Genomic profiles and transcriptomic microenvironments in 2 patients with synchronous lung adenocarcinoma and lung squamous cell carcinoma: a case report. 61
32005243 2020
30
Role of downregulated ADARB1 in lung squamous cell carcinoma. 61
32016472 2020
31
Identification of expression signatures for non-small-cell lung carcinoma subtype classification. 61
31297509 2020
32
Histologic transformation of lung cancer during pembrolizumab therapy: A case report. 61
31944570 2020
33
Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer. 61
31548347 2020
34
Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients. 61
32007320 2020
35
Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry. 61
31882501 2020
36
Elaboration of a multimodal MRI-based radiomics signature for the preoperative prediction of the histological subtype in patients with non-small-cell lung cancer. 61
31964407 2020
37
Successful Treatment for Hypercalcemia due to Cosecretion of Parathyroid Hormone-Related Protein and 1,25-Dihydroxyvitamin D3 in Non-Small-Cell Lung Cancer: A Case Report and Literature Review. 61
31976112 2020
38
Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients. 61
31692283 2020
39
[Intervention of Vascular Dysplasia Caused by Different Mechanisms - Anlotinib for Right Lung Squamous Cell Carcinoma Combined with Thromboangiitis Obliterans: A Case Report and Literature Review]. 61
31948540 2020
40
A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis. 61
31241180 2020
41
Integration of multi-omics data to mine cancer-related gene modules. 61
32019413 2019
42
Transcriptional profiling of long-intergenic noncoding RNAs in lung squamous cell carcinoma and its value in diagnosis and prognosis. 61
31617686 2019
43
Identification of lncRNA biomarkers in lung squamous cell carcinoma using comprehensive analysis of lncRNA mediated ceRNA network. 61
31364871 2019
44
Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma. 61
31836430 2019
45
ASO Author Reflections: PD-L2 Expression in Lung Squamous Cell Carcinoma-One of the Potential Important Prognostic Factors. 61
31385129 2019
46
A surgical case of synchronous solitary splenic metastasis from lung squamous cell carcinoma: report of a case and review of the literature. 61
31845086 2019
47
Long noncoding RNA FAM201A mediates the metastasis of lung squamous cell cancer via regulating ABCE1 expression. 61
31841188 2019
48
Identification and validation of key genes associated with non-small-cell lung cancer. 61
31127628 2019
49
Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions. 61
31699669 2019
50
LncRNA HULC promotes lung squamous cell carcinoma by regulating PTPRO via NF-κB. 61
31448453 2019

Variations for Lung Squamous Cell Carcinoma

ClinVar genetic disease variations for Lung Squamous Cell Carcinoma:

6 (show top 50) (show all 272) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53):c.832C>A (p.Pro278Thr)SNV Likely pathogenic,drug response 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
3 TP53 NM_000546.5(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
4 PIK3CA NM_006218.4(PIK3CA):c.2176G>A (p.Glu726Lys)SNV Pathogenic 376476 rs867262025 3:178938934-178938934 3:179221146-179221146
5 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
6 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
7 TP53 NM_000546.5(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
8 EGFR NM_005228.5(EGFR):c.2492G>A (p.Arg831His)SNV Pathogenic 560007 rs150036236 7:55259434-55259434 7:55191741-55191741
9 TP53 NM_000546.5(TP53):c.584T>C (p.Ile195Thr)SNV Pathogenic 216077 rs760043106 17:7578265-7578265 17:7674947-7674947
10 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln)SNV Pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
11 TP53 NM_000546.5(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
12 TP53 NM_000546.5(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
13 TP53 NM_000546.5(TP53):c.725G>A (p.Cys242Tyr)SNV Pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
14 TP53 NM_000546.5(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
15 TP53 NM_000546.5(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
16 TP53 NM_000546.5(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
17 TP53 NM_000546.5(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
18 KRAS NM_033360.4(KRAS):c.34G>C (p.Gly12Arg)SNV Pathogenic 12579 rs121913530 12:25398285-25398285 12:25245351-25245351
19 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
20 FGFR2 NM_022970.3(FGFR2):c.870G>C (p.Trp290Cys)SNV Pathogenic 13281 rs121918499 10:123279562-123279562 10:121520048-121520048
21 PTPN11 NM_002834.4(PTPN11):c.226G>A (p.Glu76Lys)SNV Pathogenic 13336 rs121918464 12:112888210-112888210 12:112450406-112450406
22 PTPN11 NM_002834.4(PTPN11):c.227A>G (p.Glu76Gly)SNV Pathogenic 13338 rs121918465 12:112888211-112888211 12:112450407-112450407
23 PTPN11 NM_002834.4(PTPN11):c.227A>C (p.Glu76Ala)SNV Pathogenic 13339 rs121918465 12:112888211-112888211 12:112450407-112450407
24 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
25 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
26 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
27 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg)SNV Pathogenic 13970 rs121913357 7:140481403-140481403 7:140781603-140781603
28 BRAF NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala)SNV Pathogenic 13971 rs121913355 7:140481402-140481402 7:140781602-140781602
29 BRAF NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu)SNV Pathogenic 13974 rs121913355 7:140481402-140481402 7:140781602-140781602
30 FGFR3 NM_000142.4(FGFR3):c.742C>T (p.Arg248Cys)SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
31 FGFR3 NM_000142.4(FGFR3):c.746C>G (p.Ser249Cys)SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
32 PIK3CA NM_006218.4(PIK3CA):c.1258T>C (p.Cys420Arg)SNV Pathogenic 31945 rs121913272 3:178927980-178927980 3:179210192-179210192
33 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
34 BRAF NM_004333.6(BRAF):c.1406G>T (p.Gly469Val)SNV Pathogenic 44803 rs121913355 7:140481402-140481402 7:140781602-140781602
35 EGFR NM_005228.5(EGFR):c.2303G>T (p.Ser768Ile)SNV Pathogenic 45251 rs121913465 7:55249005-55249005 7:55181312-55181312
36 TP53 NM_000546.5(TP53):c.488A>G (p.Tyr163Cys)SNV Pathogenic 127814 rs148924904 17:7578442-7578442 17:7675124-7675124
37 TP53 NM_000546.5(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
38 TP53 NM_000546.5(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
39 TP53 NM_000546.5(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
40 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
41 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
42 TP53 NM_000546.5(TP53):c.706T>G (p.Tyr236Asp)SNV Pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
43 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
44 TP53 NM_000546.5(TP53):c.833C>T (p.Pro278Leu)SNV Pathogenic 232497 rs876659802 17:7577105-7577105 17:7673787-7673787
45 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
46 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys)SNV Pathogenic 376470 rs1057519925 3:178928079-178928079 3:179210291-179210291
47 PTEN NM_000314.7(PTEN):c.389G>T (p.Arg130Leu)SNV Pathogenic/Likely pathogenic 376509 rs121909229 10:89692905-89692905 10:87933148-87933148
48 TP53 NM_000546.5(TP53):c.731G>A (p.Gly244Asp)SNV Pathogenic/Likely pathogenic 372785 rs985033810 17:7577550-7577550 17:7674232-7674232
49 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)SNV Pathogenic/Likely pathogenic,drug response 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
50 NFE2L2 NM_006164.5(NFE2L2):c.235G>A (p.Glu79Lys)SNV Pathogenic/Likely pathogenic 376466 rs1057519922 2:178098810-178098810 2:177234082-177234082

Cosmic variations for Lung Squamous Cell Carcinoma:

9 (show top 50) (show all 46804)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263727 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 24
2 COSM87596300 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.3177G>C p.V1059= 2:135200405-135200405 24
3 COSM92052275 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1662G>T p.L554F 7:89334644-89334644 24
4 COSM92062218 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1610A>G p.K537R 7:89334592-89334592 24
5 COSM92044981 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.983A>G p.N328S 7:89333965-89333965 24
6 COSM92017258 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.743G>A p.C248Y 7:89333725-89333725 24
7 COSM92016873 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.232G>C p.D78H 7:89218278-89218278 24
8 COSM92047471 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.3484C>T p.Q1162* 7:89336466-89336466 24
9 COSM88573896 ZNF804A lung,NS,carcinoma,squamous cell carcinoma c.163G>T p.A55S 2:184866420-184866420 24
10 COSM137961812 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.386G>A p.R129H 16:2002647-2002647 24
11 COSM94776745 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.934T>A p.C312S 18:25226984-25226984 24
12 COSM94799739 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.1417C>T p.P473S 18:25226501-25226501 24
13 COSM90068315 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.1064G>T p.C355F 7:57120351-57120351 24
14 COSM86289413 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 24
15 COSM85262562 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 24
16 COSM85263435 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 24
17 COSM143112283 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 24
18 COSM143104196 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 13:20006558-20006558 24
19 COSM143112460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 24
20 COSM143103178 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 24
21 COSM129142258 ZIC4 lung,NS,carcinoma,squamous cell carcinoma c.747G>A p.T249= 3:147395943-147395943 24
22 COSM85617592 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.138C>T p.A46= 3:147410250-147410250 24
23 COSM85619505 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.99G>T p.V33= 3:147410211-147410211 24
24 COSM85617600 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.587G>A p.G196D 3:147410699-147410699 24
25 COSM85618817 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.244C>T p.H82Y 3:147410356-147410356 24
26 COSM85617734 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.430C>G p.P144A 3:147410542-147410542 24
27 COSM85619514 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.979A>T p.T327S 3:147411091-147411091 24
28 COSM85618249 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.64C>A p.H22N 3:147410176-147410176 24
29 COSM127411056 ZFHX4 lung,NS,carcinoma,squamous cell carcinoma c.2919G>T p.L973= 8:76707874-76707874 24
30 COSM149303773 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 24
31 COSM149282130 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.6884A>T p.Q2295L 16:72795798-72795798 24
32 COSM149318853 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 24
33 COSM149318882 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 24
34 COSM149268808 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 24
35 COSM149260552 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 24
36 COSM149316595 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.4628G>A p.R1543H 16:72798054-72798054 24
37 COSM149303017 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 24
38 COSM149309579 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 24
39 COSM149263533 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 24
40 COSM149322707 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 24
41 COSM149308605 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1724A>C p.E575A 16:72958422-72958422 24
42 COSM149327483 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 24
43 COSM149265687 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 24
44 COSM149269636 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 24
45 COSM149263422 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 24
46 COSM149332384 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1513G>T p.D505Y 16:72958633-72958633 24
47 COSM149290601 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 24
48 COSM149305555 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1408G>T p.E470* 16:72958738-72958738 24
49 COSM149259619 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1282A>T p.T428S 16:72958864-72958864 24
50 COSM149259608 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10766C>G p.S3589C 16:72787510-72787510 24

Copy number variations for Lung Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 61)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13957 1 101664084 102994090 Loss COL11A1 Lung squamous cell carcinoma
2 18603 1 146800000 147200000 Loss LOC645166 Lung squamous cell carcinoma
3 18604 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
4 18605 1 146800000 147200000 Loss NBPF16 Lung squamous cell carcinoma
5 18606 1 146800000 147200000 Loss PPIAL4E Lung squamous cell carcinoma
6 47066 10 89540134 89615643 Loss PTEN Lung squamous cell carcinoma
7 51887 11 132926079 134452384 Loss ACAD8 Lung squamous cell carcinoma
8 58625 11 68821296 70110392 Gain CCND1 Lung squamous cell carcinoma
9 58626 11 68821296 70110392 Gain PPFIA1 Lung squamous cell carcinoma
10 79487 13 72396304 72490843 Loss Lung squamous cell carcinoma
11 89148 15 100100000 100300000 Loss OR4F15 Lung squamous cell carcinoma
12 89149 15 100100000 100300000 Loss OR4F4 Lung squamous cell carcinoma
13 89150 15 100100000 100300000 Loss OR4F6 Lung squamous cell carcinoma
14 105616 16 80626349 81449546 Loss Lung squamous cell carcinoma
15 107157 17 12394069 12459756 Loss Lung squamous cell carcinoma
16 118123 17 7571720 7590868 Mutation TP53 Lung squamous cell carcinoma
17 122933 18 64017241 75522477 Loss CD226 Lung squamous cell carcinoma
18 122934 18 64017241 75522477 Loss MBP Lung squamous cell carcinoma
19 122935 18 64017241 75522477 Loss RTTN Lung squamous cell carcinoma
20 122936 18 64017241 75522477 Loss SOCS6 Lung squamous cell carcinoma
21 128995 19 43840068 44336812 Gain AKT2 Lung squamous cell carcinoma
22 128996 19 43840068 44336812 Gain ECH1 Lung squamous cell carcinoma
23 130187 19 47900000 48300000 Loss PSG1 Lung squamous cell carcinoma
24 130188 19 47900000 48300000 Loss PSG11 Lung squamous cell carcinoma
25 130189 19 47900000 48300000 Loss PSG2 Lung squamous cell carcinoma
26 130190 19 47900000 48300000 Loss PSG3 Lung squamous cell carcinoma
27 130191 19 47900000 48300000 Loss PSG6 Lung squamous cell carcinoma
28 130192 19 47900000 48300000 Loss PSG7 Lung squamous cell carcinoma
29 130193 19 47900000 48300000 Loss PSG8 Lung squamous cell carcinoma
30 131640 19 55600000 55700000 Gain ASPDH Lung squamous cell carcinoma
31 131641 19 55600000 55700000 Gain C19orf63 Lung squamous cell carcinoma
32 131642 19 55600000 55700000 Gain FAM71E1 Lung squamous cell carcinoma
33 131643 19 55600000 55700000 Gain JOSD2 Lung squamous cell carcinoma
34 131644 19 55600000 55700000 Gain MYBPC2 Lung squamous cell carcinoma
35 131645 19 55600000 55700000 Gain NAPSA Lung squamous cell carcinoma
36 131646 19 55600000 55700000 Gain NR1H2 Lung squamous cell carcinoma
37 131647 19 55600000 55700000 Gain POLD1 Lung squamous cell carcinoma
38 131648 19 55600000 55700000 Gain SPIB Lung squamous cell carcinoma
39 149556 11 35116992 35210525 Loss IN Lung squamous cell carcinoma
40 149667 2 91000000 91500000 Loss GGT8P Lung squamous cell carcinoma
41 149668 2 91000000 91500000 Loss LOC654342 Lung squamous cell carcinoma
42 172539 3 183473858 183941579 Gain SOX2 Lung squamous cell carcinoma
43 172540 3 183473858 183941579 Gain TP73L Lung squamous cell carcinoma
44 179006 3 84414538 85858393 Loss POU1F1 Lung squamous cell carcinoma
45 181932 4 130278523 134426567 Loss PLK4 Lung squamous cell carcinoma
46 185649 4 20391110 20848036 Loss BST1 Lung squamous cell carcinoma
47 185650 4 20391110 20848036 Loss PI4K2B Lung squamous cell carcinoma
48 185651 4 20391110 20848036 Loss SLIT2 Lung squamous cell carcinoma
49 191445 5 1 1510601 Gain TERT Lung squamous cell carcinoma
50 202010 5 76066702 76539988 Loss HTR1A Lung squamous cell carcinoma

Expression for Lung Squamous Cell Carcinoma

Search GEO for disease gene expression data for Lung Squamous Cell Carcinoma.

Pathways for Lung Squamous Cell Carcinoma

Pathways related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 118)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.64 TP53 PTPN11 PIK3CA KRAS HRAS FGFR3
2
Show member pathways
13.6 PTPN11 PIK3CA KRAS HRAS FGFR3 FGFR2
3
Show member pathways
13.55 TP53 PTPN11 PTEN PIK3CA KRAS HRAS
4
Show member pathways
13.47 TP53 PTPN11 PIK3CA KRAS HRAS FGFR3
5
Show member pathways
13.4 PTPN11 PTEN KRAS HRAS FGFR3 FGFR2
6
Show member pathways
13.22 TP53 PTPN11 PTEN PIK3CA FGFR3 FGFR2
7
Show member pathways
13.2 TP53 PIK3CA KRAS HRAS EGFR BRAF
8
Show member pathways
13.17 TP53 PTEN KRAS HRAS FGFR3 FGFR2
9
Show member pathways
13.08 TP53 PTEN PIK3CA KRAS HRAS FGFR3
10
Show member pathways
13.05 TP53 PTEN PIK3CA KRAS HRAS EGFR
11
Show member pathways
13.03 PTPN11 PTEN PIK3CA KRAS HRAS EGFR
12
Show member pathways
13 PTEN PIK3CA KRAS HRAS EGFR BRAF
13
Show member pathways
12.97 PTPN11 PIK3CA KRAS HRAS FGFR3 FGFR2
14
Show member pathways
12.96 PTEN PIK3CA KRAS HRAS FGFR3 FGFR2
15
Show member pathways
12.93 PIK3CA KRAS HRAS EGFR BRAF
16
Show member pathways
12.91 TP53 PTPN11 PTEN PIK3CA KRAS HRAS
17
Show member pathways
12.89 PTPN11 PTEN PIK3CA KRAS HRAS BRAF
18 12.87 TP53 KRAS HRAS FGFR3 FGFR2 EGFR
19
Show member pathways
12.81 TP53 PTPN11 PTEN PIK3CA KRAS HRAS
20
Show member pathways
12.8 PTPN11 PIK3CA KRAS HRAS FGFR3 FGFR2
21
Show member pathways
12.77 TP53 KRAS HRAS EGFR BRAF
22 12.74 PIK3CA KRAS HRAS FGFR3 FGFR2 EGFR
23
Show member pathways
12.73 PTPN11 PTEN PIK3CA KRAS HRAS EGFR
24
Show member pathways
12.73 TP53 PTEN PIK3CA KRAS HRAS FGFR2
25
Show member pathways
12.73 TP53 PTPN11 PTEN PIK3CA KRAS HRAS
26
Show member pathways
12.73 TP53 TERC PTEN PIK3CA NFE2L2 KRAS
27
Show member pathways
12.71 TP53 PTPN11 PIK3CA KRAS HRAS EGFR
28
Show member pathways
12.69 PTPN11 PTEN PIK3CA KRAS HRAS
29
Show member pathways
12.66 PTPN11 PIK3CA KRAS HRAS FGFR3 FGFR2
30 12.63 TP53 PTEN PIK3CA KRAS HRAS FGFR3
31
Show member pathways
12.62 PTPN11 PIK3CA KRAS HRAS BRAF
32
Show member pathways
12.62 TP53 PIK3CA KRAS HRAS EGFR BRAF
33
Show member pathways
12.59 PTPN11 PTEN PIK3CA KRAS HRAS
34
Show member pathways
12.52 PTPN11 PIK3CA KRAS HRAS EGFR
35
Show member pathways
12.52 PTPN11 PTEN PIK3CA KRAS HRAS BRAF
36
Show member pathways
12.52 TP53 PIK3CA KRAS HRAS FGFR3 FGFR2
37
Show member pathways
12.51 PTPN11 PIK3CA KRAS HRAS BRAF
38
Show member pathways
12.51 TP53 PTPN11 PTEN PIK3CA HRAS
39
Show member pathways
12.51 PIK3CA KRAS HRAS FGFR3 FGFR2 EGFR
40
Show member pathways
12.51 PTPN11 PIK3CA KRAS HRAS FGFR3 FGFR2
41
Show member pathways
12.49 PTPN11 PIK3CA FGFR3 FGFR2
42 12.49 HRAS FGFR3 FGFR2 EGFR
43
Show member pathways
12.47 HRAS FGFR3 FGFR2 EGFR
44 12.46 TP53 PTEN PIK3CA KRAS HRAS
45
Show member pathways
12.44 PTPN11 PIK3CA HRAS EGFR
46
Show member pathways
12.44 PTPN11 PTEN PIK3CA KRAS HRAS
47 12.42 TP53 TERC PTEN PIK3CA NFE2L2 KRAS
48
Show member pathways
12.41 TP53 PTPN11 PTEN PIK3CA KRAS HRAS
49
Show member pathways
12.39 TP53 PTPN11 PIK3CA HRAS
50 12.39 TP53 PIK3CA KRAS HRAS

GO Terms for Lung Squamous Cell Carcinoma

Biological processes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.85 PTEN KRAS HRAS FGFR3 FGFR2 EGFR
2 positive regulation of gene expression GO:0010628 9.8 TP53 PTEN NFE2L2 KRAS HRAS BRAF
3 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 PIK3CA EGFR BRAF
4 liver development GO:0001889 9.78 PIK3CA KRAS EGFR
5 fibroblast growth factor receptor signaling pathway GO:0008543 9.77 PTPN11 FGFR3 FGFR2
6 Ras protein signal transduction GO:0007265 9.76 TP53 KRAS HRAS
7 negative regulation of neuron apoptotic process GO:0043524 9.76 PIK3CA KRAS HRAS BRAF
8 peptidyl-tyrosine phosphorylation GO:0018108 9.73 FGFR3 FGFR2 EGFR BRAF
9 positive regulation of epithelial cell proliferation GO:0050679 9.72 HRAS FGFR2 EGFR
10 positive regulation of MAP kinase activity GO:0043406 9.71 KRAS HRAS EGFR
11 cellular response to hypoxia GO:0071456 9.71 TP53 TERC PTEN NFE2L2
12 epidermal growth factor receptor signaling pathway GO:0007173 9.65 PTPN11 PIK3CA EGFR
13 organ growth GO:0035265 9.61 PTPN11 FGFR2
14 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.59 TP53 EGFR
15 positive regulation of phospholipase activity GO:0010518 9.58 FGFR3 FGFR2
16 endochondral bone growth GO:0003416 9.57 FGFR3 FGFR2
17 regulation of axon regeneration GO:0048679 9.56 PTEN BRAF
18 cellular response to drug GO:0035690 9.56 TP53 NFE2L2 EGFR BRAF
19 positive regulation of protein kinase B signaling GO:0051897 9.55 PTPN11 PIK3CA FGFR3 FGFR2 EGFR
20 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.52 TP53 NFE2L2
21 response to isolation stress GO:0035900 9.51 KRAS HRAS
22 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.49 TP53 NFE2L2
23 MAPK cascade GO:0000165 9.43 KRAS HRAS FGFR3 FGFR2 EGFR BRAF
24 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.17 PTPN11 PTEN HRAS FGFR3 FGFR2 EGFR

Molecular functions related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 FGFR3 FGFR2 EGFR
2 insulin receptor substrate binding GO:0043560 9.37 PTPN11 PIK3CA
3 transcription cofactor binding GO:0001221 9.32 TP53 NFE2L2
4 protein tyrosine kinase activity GO:0004713 9.26 FGFR3 FGFR2 EGFR BRAF
5 fibroblast growth factor-activated receptor activity GO:0005007 9.16 FGFR3 FGFR2
6 nucleotide binding GO:0000166 9.1 KRAS HRAS FGFR3 FGFR2 EGFR BRAF

Sources for Lung Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....